112 related articles for article (PubMed ID: 3391874)
1. Fate of single oral doses of erythromycin acistrate, erythromycin stearate and pelleted erythromycin base analysed by mass-spectrometry in plasma of healthy human volunteers.
Männistö PT; Taskinen J; Ottoila P; Solkinen A; Vuorela A; Nykänen S
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():33-43. PubMed ID: 3391874
[TBL] [Abstract][Full Text] [Related]
2. Absorption of erythromycin acistrate and erythromycin base in the fasting and non-fasting state.
Tuominen RK; Männistö PT; Pohto P; Solkinen A; Vuorela A
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():45-55. PubMed ID: 3391875
[TBL] [Abstract][Full Text] [Related]
3. Tonsillar penetration of erythromycin and its 2'-acetyl ester in patients with chronic tonsillitis.
Savolainen S; Männistö PT; Gordin A; Antikainen R; Haataja H; Tuominen RK; Ylikoski J
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():73-84. PubMed ID: 3391878
[TBL] [Abstract][Full Text] [Related]
4. Effect of food on absorption and hydrolysis of erythromycin acistrate.
Järvinen A; Nykänen S; Mattila J; Haataja H
Arzneimittelforschung; 1992 Jan; 42(1):73-6. PubMed ID: 1586385
[TBL] [Abstract][Full Text] [Related]
5. Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base.
Wuolijoki E; Flygare U; Hildén M; Hurme J; Järvinen H; Leskinen J; Pynnönen S; Riikonen A; Salomaa V; Seuri M
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():107-12. PubMed ID: 3391872
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic concentration in suction skin blister fluid and saliva after repeated dosage of erythromycin acistrate and erythromycin base.
Tuominen RK; Männistö PT; Solkinen A; Vuorela A; Pohto P; Haataja H
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():57-65. PubMed ID: 3391876
[TBL] [Abstract][Full Text] [Related]
7. Absorption of erythromycin stearate and enteric-coated erythromycin base after a single oral dose immediately before breakfast.
Schreiner A; Digranes A
Infection; 1984; 12(5):345-8. PubMed ID: 6511088
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.
Gordin A; Männistö PT; Antikainen R; Savolainen S; Ylikoski J; Kokkonen P; Rauramaa V
Antimicrob Agents Chemother; 1988 Jul; 32(7):1019-24. PubMed ID: 3190191
[TBL] [Abstract][Full Text] [Related]
9. Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
Tuominen RK; Lehtinen R; Peltola J; Wikberg R; Gordin A; Kokkonen P; Pohto P
Oral Surg Oral Med Oral Pathol; 1991 Jun; 71(6):684-8. PubMed ID: 2062521
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts.
Gordin A; Salmi HA; Antikainen R
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():93-9. PubMed ID: 3391881
[TBL] [Abstract][Full Text] [Related]
11. Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
Gordin A; Kalima S; Hulmi S; Mäkelä P; Antikainen R
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():85-92. PubMed ID: 3391879
[TBL] [Abstract][Full Text] [Related]
12. The influence of food on the bioavailability of new formulations of erythromycin stearate and base.
Rutland J; Berend N; Marlin GE
Br J Clin Pharmacol; 1979 Oct; 8(4):343-7. PubMed ID: 508509
[TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
DiSanto AR; Tserng KY; Chodos DJ; DeSante KA; Albert KS; Wagner JG
J Clin Pharmacol; 1980 Jul; 20(7):437-43. PubMed ID: 7430412
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin.
Tjandramaga TB; Van Hecken A; Mullie A; Verbesselt R; De Schepper PJ; Verbist L; Josefsson K
Pharmacology; 1984; 29(6):305-11. PubMed ID: 6334320
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and stability of erythromycin delayed release tablets.
Ogwal S; Xide TU
Afr Health Sci; 2001 Dec; 1(2):90-6. PubMed ID: 12789122
[TBL] [Abstract][Full Text] [Related]
16. Influence of study design in assessing food effects on absorption of erythromycin base and erythromycin stearate.
DiSanto AR; Chodos DJ
Antimicrob Agents Chemother; 1981 Aug; 20(2):190-6. PubMed ID: 7283417
[TBL] [Abstract][Full Text] [Related]
17. Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.
Yakatan GJ; Rasmussen CE; Feis PJ; Wallen S
J Clin Pharmacol; 1985; 25(1):36-42. PubMed ID: 3871797
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.
Männistö PT; Hanhijärvi H; Havas A; Vuorela A; Komulainen H; Rauramaa V
J Pharmacol Exp Ther; 1989 Sep; 250(3):1028-33. PubMed ID: 2778707
[TBL] [Abstract][Full Text] [Related]
19. The value of comparative bioavailability studies of marketed drugs in drug control. An example with erythromycin stearate.
Venho VM; Palva ES; Konno K; Stenfors E
Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):445-7. PubMed ID: 3683018
[TBL] [Abstract][Full Text] [Related]
20. Erythromycin and 2'-acetyl erythromycin concentrations in plasma and pelvic tissues after repeated doses of erythromycin acistrate.
Lehtonen L; Wikberg R; Karhunen M; Kokkonen P; Tuominen R
Arzneimittelforschung; 1993 Jan; 43(1):53-6. PubMed ID: 8447849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
